Indy (317) 643-4444 Fishers (317) 567-9100
Tirzepatide Eli Lilly

Zepbound®

FDA-Approved Specifically for Weight Loss

Zepbound® (tirzepatide) is FDA-approved specifically for chronic weight management—the same powerful dual-action medication as Mounjaro, now with official weight loss approval.

Regulates appetite
Balances blood sugar
Reduces cravings
Get Started Learn more
20-22% average weight loss
Once Weekly Injection
$275 Per month
Save 74% vs. ~$1050 retail
Basics Benefits How It Works Safety FAQ

What is Zepbound?

Zepbound received FDA approval in November 2023 as a groundbreaking treatment for chronic weight management. It contains tirzepatide, the same active ingredient as Mounjaro, but is specifically indicated and dosed for weight loss rather than diabetes.

Clinical Trial Results

The SURMOUNT trials showed participants on Zepbound lost an average of 22.5% of their body weight—approximately 52 pounds for the average participant—making it the most effective FDA-approved weight loss medication.

FDA Approved For

  • Chronic weight management in adults with BMI ≥30 (obesity)
  • Chronic weight management in adults with BMI ≥27 with at least one weight-related condition

Quick Facts

Generic Name
Tirzepatide
Manufacturer
Eli Lilly
Drug Class
Dual GIP/GLP-1 Receptor Agonist
Administration
Subcutaneous injection
Frequency
Once Weekly

Benefits of Zepbound

1

FDA-approved specifically for weight loss

2

Highest average weight loss of any approved medication (20-22%)

3

Dual GIP/GLP-1 mechanism for superior results

4

Once-weekly convenient injection

5

Dramatic reduction in hunger and cravings

6

Improvements in blood pressure and cholesterol

7

Better energy levels as weight decreases

8

Reduced risk of weight-related diseases

How Zepbound Works

Zepbound activates both GIP and GLP-1 receptors, creating a dual-action effect that surpasses traditional single-receptor weight loss medications. It reduces hunger signals, increases feelings of fullness, slows digestion, and improves how your body processes food—all working together for maximum weight loss.

Dual-Action Mechanism

GLP-1 Receptor

Slows gastric emptying, reduces appetite, signals fullness to brain

+

GIP Receptor

Enhances insulin response, improves fat metabolism, amplifies GLP-1 effects

This dual mechanism is why Tirzepatide shows 5-7% greater weight loss than GLP-1-only medications in clinical trials.

Ideal Candidates

  • Adults with BMI ≥30 seeking significant weight loss
  • Adults with BMI ≥27 plus high blood pressure, diabetes, or high cholesterol
  • Those wanting the most effective FDA-approved weight loss medication
  • Patients who prefer official weight loss indication over off-label use
  • People who have tried other weight loss methods without success

Not Recommended For

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2
  • Pregnancy or planning to become pregnant
  • Currently breastfeeding
  • History of pancreatitis
  • Severe kidney disease

Safety Information

Black Box Warning

Tirzepatide causes thyroid C-cell tumors in rodents. It is not known if Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound is contraindicated in patients with a personal or family history of MTC or MEN 2.

Common Side Effects

Most side effects improve as your body adjusts to the medication.

  • Nausea ~24%
  • Diarrhea ~18%
  • Vomiting ~12%
  • Constipation ~10%
  • Abdominal pain ~8%

Serious Side Effects

Rare but important. Contact your provider if you experience any of these.

  • Pancreatitis - stop medication and seek care for severe abdominal pain radiating to back
  • Gallbladder disease - rapid weight loss can increase gallstone risk
  • Kidney problems - stay well hydrated, especially if experiencing GI symptoms
  • Severe allergic reactions - seek immediate care for swelling, difficulty breathing

Frequently Asked Questions

Yes and no. Both contain tirzepatide and work identically. The difference is FDA approval: Mounjaro is approved for diabetes, Zepbound for weight loss. We can prescribe either based on your needs and insurance coverage.

Zepbound (tirzepatide) works on TWO hormone receptors (GIP + GLP-1) while Wegovy (semaglutide) works on one (GLP-1 only). This dual action makes Zepbound approximately 5-7% more effective for weight loss in clinical trials.

Weight loss medications work best as long-term treatments. Most patients take Zepbound for at least 12-18 months, with many continuing indefinitely. Stopping typically leads to weight regain. Our team helps you find a sustainable plan.

Insurance coverage varies widely. Some plans cover weight loss medications; others don't. At Premier Weight Loss, our pricing is often less than insurance copays elsewhere, making coverage less critical.

Most patients lose 15-25% of their starting weight over 12-18 months. Results vary based on starting weight, dose tolerance, diet, and activity. Some patients exceed 25% loss. We track your progress monthly and adjust as needed.

Compare Medications

Tirzepatide

Mounjaro®

20-22% $275/mo
Learn more Semaglutide

Wegovy®

15-17% $175/mo
Learn more Semaglutide

Ozempic®

14-15% $175/mo
Learn more
Compare All Medications

Ready to Start Zepbound?

Take our quick eligibility quiz or schedule a consultation with our medical team.

Check If You Qualify
Indianapolis (317) 643-4444Fishers (317) 567-9100